1. Home
  2. VTGN vs MBAI Comparison

VTGN vs MBAI Comparison

Compare VTGN & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

HOLD

Current Price

$0.29

Market Cap

10.8M

Sector

Health Care

ML Signal

HOLD

MBAI

Check-Cap Ltd. Ordinary Share

HOLD

Current Price

$4.21

Market Cap

8.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
VTGN
MBAI
Founded
1998
2004
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.8M
8.9M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
VTGN
MBAI
Price
$0.29
$4.21
Analyst Decision
Hold
Analyst Count
3
0
Target Price
★ $0.90
N/A
AVG Volume (30 Days)
★ 18.6M
25.7K
Earning Date
06-16-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
★ N/A
Revenue This Year
$124.49
N/A
Revenue Next Year
$353.99
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.20
$0.95
52 Week High
$5.14
$10.21

Technical Indicators

Market Signals
Indicator
VTGN
MBAI
Relative Strength Index (RSI) 55.48 31.15
Support Level $0.22 $1.19
Resistance Level $0.32 $6.81
Average True Range (ATR) 0.04 0.42
MACD 0.01 -0.40
Stochastic Oscillator 20.16 5.60

Price Performance

Historical Comparison
VTGN
MBAI

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

About MBAI Check-Cap Ltd. Ordinary Share

MBody AI Ltd is an embodied artificial intelligence company. Its core technology is the MBody AI Orchestrator (Orchestrator), a proprietary, hardware-agnostic software platform that serves as an intelligence layer designed to enable autonomous systems to operate, coordinate, and improve more effectively. MBody AI does not manufacture robots; it makes third-party robots more intelligent and coordinated through the Orchestrator and deploys them at customer sites together with its software and related services. Each deployment is designed to generate proprietary operational data. Its initial commercial focus is the hospitality industry, with potential applications across other labor-intensive sectors, including warehousing, office management, and healthcare.

Share on Social Networks: